Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikvah, Israel.
Leuk Lymphoma. 2021 Jul;62(7):1544-1553. doi: 10.1080/10428194.2021.1873320. Epub 2021 Jan 28.
The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional response assessments. MRD is being incorporated as an endpoint in an increasing number of studies and had been repeatedly shown to be both a predictive marker of response to treatment and a prognostic marker for future relapse. However, those results should be cautiously interpreted due to non-uniform reporting and the need for longer follow up to assess for sustained MRD negativity. This review aims to critically analyze the key MRD aspects including the current evidence supporting the use of MRD in clinical practice and the pitfalls of the various methods used to assess MRD. The utility of MRD for light chain (AL) amyloidosis will also be discussed.
高效多发性骨髓瘤 (MM) 治疗方法的出现可能使治愈成为可能，这凸显了对高度敏感的可测量残留疾病 (MRD) 技术的需求，以替代传统的反应评估。MRD 作为越来越多研究的终点被纳入，并已反复证明是治疗反应的预测标志物，也是未来复发的预后标志物。然而，由于报告不统一以及需要更长时间的随访以评估持续的 MRD 阴性，这些结果应谨慎解释。本综述旨在批判性地分析关键的 MRD 方面，包括目前支持 MRD 在临床实践中应用的证据，以及评估 MRD 时使用的各种方法的缺陷。MRD 在轻链 (AL) 淀粉样变性中的应用也将进行讨论。
